EFS
ALNY icon

Essex Financial Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Essex Financial Services’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$261K Buy
866
+159
+22% +$48K 0.01% 696
2026
Q1 		$234K Buy
707
+17
+2% +$5.79K 0.01% 705
2025
Q4 		$274K Sell
690
-24
-3% -$10.6K 0.02% 636
2025
Q3 		$325K Buy
+714
New +$291K 0.02% 555

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Essex Financial Services's ALNY Position: Q2 2026 in Review

Essex Financial Services increased its Alnylam Pharmaceuticals (ALNY) stake by 22% in Q2 2026, buying an estimated $48K and bringing the position to 866 shares worth $261K. The position accounts for 0.01% of the portfolio, ranked #696.

Essex Financial Services first reported a position in ALNY in Q3 2025 and has held it in 4 quarters since. The position peaked at $325K in Q3 2025. 496 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Essex Financial Services held 866 shares of Alnylam Pharmaceuticals worth $261K as of Q2 2026.
  • Essex Financial Services bought 159 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $48K.
  • Alnylam Pharmaceuticals made up 0.01% of Essex Financial Services's portfolio in Q2 2026, its #696 holding.
  • Essex Financial Services first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Essex Financial Services's Alnylam Pharmaceuticals position peaked at $325K in Q3 2025.
  • 496 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Essex Financial Services's 13F filing for Q2 2026, filed 10 Aug 2026.